Hospital.Help

Frankfurt am Main – The significant drop in prices since the introduction of generics has improved the cost-effectiveness of statin therapy. According to a study in medRXiv (2024; DOI: 10.1101/2024.08.14.24311999), the use would be justifiable if the 10-year risk of cardiovascular events was 9.8%. This corresponds to the recommendations of the cardiological societies. The number of statutory health insurance patients who are prescribed cholesterol-lowering drugs…